Obicetrapib shows promise in reducing Alzheimer's biomarkers

NewAmsterdam Pharma (NAMS) announced statistically significant reductions in the Alzheimer's biomarker p-tau217 with its drug obicetrapib in a prespecified analysis of its BROADWAY trial, notably reducing levels by 20.5% compared to placebo in high-risk ApoE4 carriers. This unexpected positive data, presented at the 2025 Alzheimer’s Association International Conference, expands the potential of obicetrapib beyond its primary cardiovascular indication, bolstering NAMS's robust liquidity (current ratio ~20x) and contributing to its stock's over 40% surge in the past year. While the drug was well-tolerated and regulatory discussions are planned, analyst ratings are mixed (Neutral to Buy, targets up to $52.26), reflecting both the promising new data and the extended timeline for its primary Phase 3 cardiovascular outcomes trial results in late 2026.

Analysis

NewAmsterdam Pharma (NAMS) has reported a significant positive development from its BROADWAY clinical trial, showing its lead drug candidate, obicetrapib, achieved statistically significant reductions in the Alzheimer’s disease biomarker p-tau217. The data, presented at the Alzheimer’s Association International Conference, is particularly compelling in the highest-risk patient cohort (carriers of two E4 proteins), where p-tau217 levels were reduced by 20.5% versus placebo (p=0.010). This finding unexpectedly expands the potential therapeutic application of obicetrapib, a CETP inhibitor primarily developed for LDL cholesterol reduction, into the large and underserved Alzheimer's market. Financially, the company is well-positioned to pursue this new avenue, supported by a robust current ratio of nearly 20x, indicating strong liquidity. This positive clinical news builds on existing investor confidence, which has driven the stock up over 40% in the past year. However, analyst sentiment presents a nuanced picture; while Citi, Cantor, and Stifel are bullish with price targets up to $44, Goldman Sachs initiated coverage with a Neutral rating and a $27 target, citing the extended timeline for the drug's primary Phase 3 cardiovascular outcomes data, which is not expected until late 2026. The next pivotal step will be the company's discussions with regulatory authorities regarding this new Alzheimer's data.

Key Decisions for Investors

• Investors should weigh the significant, newly identified potential in the Alzheimer's market against the primary valuation overhang, which is the long wait until late 2026 for the pivotal PREVAIL cardiovascular trial results.
• Monitor for company announcements regarding discussions with regulatory authorities, as positive feedback could serve as a major near-term catalyst and de-risk the development path for this new indication.
• Given the stock's 40% run-up and mixed analyst ratings, it may be prudent to consider the current valuation, noting that while InvestingPro suggests it is near Fair Value, the timeline for the primary endpoint could introduce volatility.
• The company's strong liquidity, evidenced by a current ratio near 20x, provides a solid foundation to fund ongoing trials, reducing near-term financing risk for current and prospective shareholders.